Clinical Trial Search

Primary: Mean Change From Baseline in Hemoglobin Levels Over the Evaluation Period (Week 28 to Week 52) — -0.04; 0.02 Grams per deciliter (g/dL)

Primary: Change From Baseline in Blood Hemoglobin Level (g/L) — 18.33; 18.52 g/L — p=0.0032

Primary: Change From Baseline to Endpoint (Week 13) in Fasting sBA Level — -23; 18; -38 umol/L

Primary: Percentage of Patients With Complete Renal Response (CRR) at Week 52 — 38.32; 44.95; 44.56; 48.33 Percentage of Participants — p=0.7271

Primary: Change in Serum Pro-collagen 1 Intact N-terminal Propeptide (P1NP) — 72.1; 67.4 ng/mL — p=0.53

Primary: Maximum Observed Plasma Concentration (Cmax) of Padsevonil for Single Dose — 366.6; 385.3; 697.4 ng/mL

Primary: Number of Pharmacists Who Objected to Participate in Dispensing Mifeprex — 4 Participants

Primary: Percentage of Participants Experiencing Aspiration — 70; 52 percentage of participants

Primary: Functional Connectivity During Nitrous Oxide — 0.1123; 0.0358; 0.1492; 0.0394 Fisher's r transformed z score — p=0.001

Primary: Number of Participants With Voluntary Movement — 1; 0 Participants

Primary: Change From Baseline in Mean Monthly Migraine Days Across the 12-Week Treatment Period — -2.48; -3.69; -3.86; -4.20 migraine days per month — p=<.0001

Primary: Number of Participants With Adverse Events and Serious Adverse Events — 91; 1; 8; 3 Participants

Primary: Rate of Enrollment (14 Days) — 540; 622; 271; 258 Participants — p=.007

Primary: Number of Participants Experiencing Preterm Births or Stillbirths — 36; 36 Participants

Primary: Number of Participants Who Met Clinical Worsening — 0; 6 Participants